Artificial Intelligence Pioneer Dr. Randy Goebel Joins CB2 Insights to Advance its Predictive Insights Platform

Globally-Recognized Machine Learning Expert Joins as Senior Advisor to Data Insights Division

TORONTO, March 14, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII) a leading global provider of predictive analytics tools, data-driven software and comprehensive services across the medical cannabis value chain, today announced that Dr. Randy Goebel, PhD. will join the Company as a Senior Advisor to its Data Insights division to further advance its predictive analytics tools and insights capabilities.

Dr. Goebel is a professor of Computing Science at the University of Alberta as well as one of the founders and a current researcher at the Alberta Machine Intelligence Institute.  He was instrumental in bringing Google’s DeepMind research centre to Canada and is actively involved in academic and industrial projects in Europe and Japan. Dr. Goebel also sits on the advisory boards for the German Research Centre for AI, the Japan Science and Technology Agency and the Japanese National Institute for Informatics. 

“There is no question that there is an urgent need for more robust usable data systems within the medical cannabis space,” said Dr. Goebel.  “I am excited to help CB2 Insights advance their platform to better exploit the critical data they ingest every day and explore cannabinoid therapy in a way that has not previously been done.”

CB2 Insights currently evaluates approximately 65,000 patients annually through its clinic network and handles millions of clinically-validated data points that work to advance the understanding of the efficacy and risks associated with cannabinoid therapy.  Moving forward, leveraging that data to create new predictive analytics tools aimed at providing a deeper level of insight to a wealth of stakeholders is key to mainstreaming cannabis into traditional healthcare.

“When it comes to artificial intelligence and machine learning, there are few minds as well respected as Dr. Goebel,” said Prad Sekar, CEO, CB2 Insights.  “We are proud of how far we have come to bring about a new level of research and data integrity to the medical cannabis industry and to now have someone of Dr. Goebel’s prominence to enhance that foundation is both humbling and exciting.”

CB2 Insights’ core mission is to guide cannabis therapy into traditional healthcare, in part through bringing Real-World Evidence and healthcare protocols to the cannabis industry.  With Dr. Goebel at the helm of the Company’s Data Advisory team, this will bolster CB2 Insights’ ability to achieve this mission.  Dr. Goebel will work with the CB2 Insights team on platform architecture and design enhancements to help serve a variety of new stakeholders to the Company such as regulatory bodies, government agencies, researchers and pharmaceutical companies from the robust set of clinically-led data collected through CB2 Insights’ other business units.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare.  We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands.  Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry. 

For more information please visit

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein. 

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.


Contact Data